New Delhi, Dec 31 (IANS) Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday.
The drug will likely dominate the obesity market, surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData, a leading data and analytics company.
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues.
“From the start, Zepbound emerged as the primary new competitor of Wegovy, and it seems that Eli Lilly has followed in some way Novo Nordisk’s strategy to increase patients’ population through investigating the drug in multiple indications,” said Costanza Alciati, pharma analyst at GlobalData.
Recently, Eli Lilly announced the results from its SURMOUNT-5 trial, comparing Zepbound and Wegovy’s efficacy on equal grounds.
Zepbound, as expected, was more effective in promoting weight loss. While Wegovy caused an average weight loss of 13.7 per cent body weight, Zepbound promoted around 20.2 per cent body weight loss in patients.
On December 20, 2024, tirzepatide also received US FDA approval for obstructive sleep apnea.
Tirzepatide is being investigated for four additional indications, including cardiovascular risk factors, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH).
“Indeed, semaglutide is approved for type 2 diabetes, obesity, and cardiovascular risk factors, and is in development for four additional indications, including chronic kidney disease,” said the report.
According to GlobalData drugs database, more than 400 companies are actively developing obesity drugs, from discovery to pre-registration candidates.
The impact of Wegovy on the obesity market has been huge. Key Opinion Leaders (KOLs) interviewed by GlobalData defined it as “revolutionary”.
With Zepbound, the revolution continues, and Eli Lilly’s drug is more potent, and perhaps negotiations with national health services will also make it more cost-effective than Wegovy, said Alciati. “So, Zepbound is expected to take the lead in the obesity market if it hasn’t already done so”.
—IANS
na/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
